



**Weill Cornell
Medicine**



New York-Presbyterian
Phyllis and David Komansky
Center for Children's Health
Weill Cornell Medical Center

Bloom Syndrome

Past, present, future

Chris Cunniff, MD
Department of Pediatrics
Division of Medical Genetics

Disclosure

I do not have a financial interest in commercial products or services related to the subject of this talk.

What I will cover

Background

Bloom Syndrome Registry

Completed work

Ongoing work

Future directions




Brief history of Bloom Syndrome

1954 report by David Bloom

3 children with growth deficiency and rash

First reported patient was of Ashkenazi background

Suggested a syndrome



Brief history of Bloom Syndrome

1965 - spontaneous chromosome breakage

1969 – first 27 patients published

1974 – increased sister chromatid exchange

1995 – *BLM* gene is a RECQ helicase




BLM functions

Helicase function unwinds DNA for replication, transcription

Maintains genome stability

Suppresses homologous recombination

Repairs damaged DNA



BLM mutations


Result in complete loss of *BLM* function

Most common gene abnormality is *BLM*^{Ash}
(c.2207–2212delATCTGA- insTAGATTC)

65 different mutations identified, many
recurrent

Present on all continents and many ethnic
groups

Mutation information available on 164 of
277 people in the BSR



Patient Registries

Observational study design

Uniform data collection

Specified outcomes

Scientific, clinical and policy purposes



Registries for evaluating patient outcomes:
<https://www.ncbi.nlm.nih.gov/books/NBK208619/>



Bloom Syndrome Registry

REDCap database of persons with Bsyn

277 registrants from over 15 countries

Biological samples on 161 individuals, mostly with trio samples

11 tumor samples

Survey enabled



Completed work

Two comprehensive reviews of Bloom syndrome published

Health supervision recommendations

Feeding and nutrition



Growth and feeding

Feeding difficulty in
infancy

Gastroesophageal
reflux common

Appetite decreased
in older persons



Feeding and nutrition

Survey based assessment of feeding patterns and behaviors

Subjects: children ages 2 to 12 years of age


Child Eating Behavior Questionnaire

8 domains such as emotional over/undereating, enjoyment of food

Feeding Assessment Questionnaire


Appetite, food preferences, eating problems

Child Eating Behavior Questionnaire (Male)



■ Bloom Male average ■ Male Average

Child Eating Behavior Questionnaire (Female)



■ Bloom Female Average ■ Female Average

FAQ Findings - Growth

63% with birth weight <3% and 100% under 10th %

89% diagnosed with failure to thrive or slow growth

67% have weight below 3%, 78% at or under 10%

67% have height at or under the 3%

FAQ Findings

Feeding:

- 56% report their child has poor appetite
- 56% report child eats limited variety of foods
- 78% report child is slow to feed
- 100% of parents report that there is NOT a physical disability affecting feeding

Feeding Support:

- 56% of patients take a nutritional supplement (fortified milk, Pediasure)
- 33% of the children had G-tubes placed

Ongoing work

Time to event analysis

Ionizing radiation

Whole genome analysis



Time to event analysis

Cancer onset and survival

Gender differences

Genotype differences



Ionizing radiation

Radiation is highly toxic in some chromosome instability disorders


Several reports of severe local toxicity and mucositis in Bsyn patients

IR and risk for secondary malignancies?




Ionizing radiation sensitivity

Clonogenic survival assay




γ H2AX assay



Whole genome sequencing

- Cells from 3 oldest and 3 youngest in BSR
- Low pass coverage to detect loss or gain of chromosome material
- High pass coverage to detect single gene changes



Future Directions

Tumor analysis

Longitudinal samples

Health supervision effectiveness

BLM pathway disorders

Facial phenotyping

Building infrastructure



Analysis of Bloom tumors

WES/WGS of Bloom tumors has not been reported

The mutation landscape of some tumors implicates
DNA repair pathways

These tumors may be sensitive to some therapies such
as PARP inhibitors

Use the signature to identify therapeutic targets

Longitudinal samples

Surveys

Multiple samples on
each person

Whole genome
sequencing

Exosome analysis



ORIGINAL ARTICLE

Health supervision for people with Bloom syndrome

Christopher Cunniff¹  | Amir Reza Djavid¹ | Steven Carrubba¹ | Bernard Cohen² |
Nathan A. Ellis³ | Carolyn Fein Levy⁴ | Stacy Jeong¹ | Howard M. Lederman⁵ |
Maria Vogiatzi⁶ | Michael F. Walsh⁷ | Ann Graham Zauber⁸

¹Division of Medical Genetics, Department of Pediatrics, Weill Cornell Medical College, New York, New York

²Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland

³Department of Cellular and Molecular Medicine, University of Arizona Cancer Center, Tucson, Arizona

⁴Division of Hematology/Oncology, Department of Pediatrics, Hofstra Northwell School of Medicine, Hempstead, New York

⁵Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland

⁶Division of Hematology/Oncology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania

⁷Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York

⁸Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York

Mutations in *TOP3A* Cause a Bloom Syndrome-like Disorder


Carol-Anne Martin,^{1,26} Kata Sarlós,^{2,26} Clare V. Logan,^{1,26} Roshan Singh Thakur,^{2,26} David A. Parry,¹ Anna H. Bizard,² Andrea Leitch,¹ Louise Cleal,¹ Nadia Shaukat Ali,³ Mohammed A. Al-Owain,⁴ William Allen,⁵ Janine Altmüller,⁶ Miriam Aza-Carmona,^{7,8} Bushra A.Y. Barakat,³ Jimena Barraza-García,^{7,8} Amber Begtrup,⁹ Massimo Bogliolo,^{8,10} Megan T. Cho,⁹ Jaime Cruz-Rojo,¹¹ Hassan Ali Mundi Dhahrabi,³ Nursel H. Elcioglu,¹² GOSgene,¹³ Gráinne S. Gorman,¹⁴ Rebekah Jobling,¹⁵ Ian Kesterton,¹⁶ Yoshihito Kishita,¹⁷ Masakazu Kohda,¹⁷ Polona Le Quesne Stabej,¹³ Asam Jassim Malallah,³ Peter Nürnberg,⁶ Akira Ohtake,¹⁸ Yasushi Okazaki,¹⁷ Roser Pujol,^{8,10} Maria José Ramirez,^{8,10} Anya Revah-Politi,¹⁹ Masaru Shimura,²⁰ Paul Stevens,¹⁶ Robert W. Taylor,¹⁴ Lesley Turner,²¹ Hywel Williams,¹³ Carolyn Wilson,⁵ Gökhan Yigit,²² Laura Zahavich,¹⁵ Fowzan S. Alkuraya,^{23,27} Jordi Surralles,^{8,10,24,27} Alejandro Iglesias,^{25,27} Kei Murayama,^{20,27} Bernd Wollnik,^{22,27} Mehul Dattani,^{13,27} Karen E. Heath,^{7,8,27} Ian D. Hickson,^{2,*} and Andrew P. Jackson^{1,*}

Bloom syndrome, caused by biallelic mutations in *BLM*, is characterized by prenatal-onset growth deficiency, short stature, an erythematous photosensitive malar rash, and increased cancer predisposition. Diagnostically, a hallmark feature is the presence of increased sister chromatid exchanges (SCEs) on cytogenetic testing. Here, we describe biallelic mutations in *TOP3A* in ten individuals with prenatal-onset growth restriction and microcephaly. *TOP3A* encodes topoisomerase III alpha (TopIII α), which binds to BLM as part of the BTRR complex, and promotes dissolution of double Holliday junctions arising during homologous recombination. We also identify a homozygous truncating variant in *RMI1*, which encodes another component of the BTRR complex, in two individuals with microcephalic dwarfism. The *TOP3A* mutations substantially reduce cellular levels of TopIII α , and consequently subjects' cells demonstrate elevated rates of SCE. Unresolved DNA recombination and/or replication intermediates persist into mitosis, leading to chromosome segregation defects and genome instability that most likely explain the growth restriction seen in these subjects and in Bloom syndrome. Clinical features of mitochondrial dysfunction are evident in several individuals with biallelic *TOP3A* mutations, consistent with the recently reported additional function of TopIII α in mitochondrial DNA decatenation. In summary, our findings establish *TOP3A* mutations as an additional cause of prenatal-onset short stature with increased cytogenetic SCEs and implicate the decatenation activity of the BTRR complex in their pathogenesis.

TOP3A



TOP3A growth



FACE2GENE

Developed by FDNA

CLINIC


FORUMS

LIBRARY
LONDON MEDICAL DATABASES

LABS

RESEARCH

ACADEMY




Smart Phenotyping.
Better Genetics.

Digital phenotyping

Computer recognition software analyzes facial features

Composite image created

Image analysis by age, gender, ethnicity, genotype



Building infrastructure



Acknowledgements

New York Community Trust
Department of Pediatrics
Clinical and Translational Science Center
Patients and Families

